A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors
- Conditions
- advanced stage non-small cell lung cancermetastatic non-small cell lung cancer1003866610029107
- Registration Number
- NL-OMON37908
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 48
1.Histologically or cytologically confirmed NSCLC locally advanced and metastatic disease stage IIIB and IV, that have an activating EGFR mutation, progressive on treatment with gefitinib or erlotinib. Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible
2. At least one unidimensionally measurable lesion meeting RECIST criteria
3. ECOG PS 0-2
4. Age > 18 years
5. Adequate organ function, including:
a. Adequate bone marrow reserve: ANC > 1.5 x 109/L, platelets > 100 x 109/L.
b. Hepatic: bilirubin <1.5 x ULN, AP, ALT, AST < 3.0 x ULN
AP, ALT, and AST <5 xULN is acceptable if the liver has tumour involvement
c. Renal: calculated creatinine clearance > 45 ml/min based on the Cockroft and Gault formula.
6. Signed informed consent
7. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 14 days prior to study enrollment.
8. Estimated life expectancy >12 weeks
9. Patient compliance and geographical proximity that allow adequate follow up.
10. NSCLC with an activating sensitising EGFR TK mutation as determined by using a well-validated and robust methodology.
1. Pregnant or lactating women
2. Patients who are poor medical risks because of non-malignant disease as well as those with active uncontrolled infection.
3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases and has been off corticosteroids for at least two weeks before enrollment.
4. Concomitant treatment with any other experimental drug under investigation.
5. Known severe hypersensitivity to gefitinib or any of the excipients of the product.
6. Presence of EGFR TK mutation reported to confer resistance to EGFR TKI: i.e., exon 20 point mutation (T790M or S768I EGFR) or exon 20 insertion as determined by using a well-validated and robust methodology.
7. Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.
8. Concomitant use of known CYP 3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
9. Previous enrolment or treatment in the present study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary Efficacy Endpoint<br /><br>After 8 weeks of treatment start all patients that are evaluated for tumour<br /><br>response and are Stable Disease or better (according to RECIST criteria) will<br /><br>be classified as *non-progressive*. The study drug will be of interest for<br /><br>further study as single agent in this tumour type if at least 24/46 (52.2%) of<br /><br>patients are *non-progressive* within 8 weeks. (Patients without post baseline<br /><br>tumour assessment will be regarded as progressive in the interim and the final<br /><br>analysis).</p><br>
- Secondary Outcome Measures
Name Time Method